Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Avanafil demonstrated significant improvement in erectile function outcomes compared to placebo, with higher scores on International Index of Erectile Function - Erectile Function (IIEF-EF)) (mean difference (MD) =4.39, 95% confidence interval (CI) [3.41, 5.37], p<0.001) and increased success rates on Sexual Encounter Profile (SEP)-2 (relative risk (RR)=3.43, 95% CI [2.79, 4.22], p<0.001) and SEP-3 (RR=2.30, 95% CI [2.01, 2.62], p<0.001).
• Avanafil 200 mg on demand ranked highest for erectile dysfunction (ED) recovery post-nerve-sparing radical prostatectomy, with SUCRA probabilities of 83.5 and 90.2 in sensitivity analyses, indicating greater effectiveness in this population.
• In a network meta-analysis of phosphodiesterase type 5 (PDE5) inhibitors, sildenafil 25 mg was identified as the most effective for enhancing IIEF, with sildenafil 50 mg also performing strongly; avanafil was less effective relative to these other PDE5 inhibitors in general ED treatment.
• Avanafil showed a higher incidence of Treatment-Emergent Adverse Events (TEAEs) compared to placebo, with a relative risk of 1.49 (95% CI [1.12, 1.96], p=0.005).
• Mirodenafil had the highest rate of adverse events, particularly flushing and headaches, while sildenafil 100 mg was associated with increased visual disorders.
• There is no population types or subgroups information available in the reviewed studies.